When TODAY.com asked doctors about Wegovy’s long-term use, some said they were comfortable prescribing Wegovy knowing a patient might take it for years, while others had major concerns. There are no long-term studies on Wegovy, and patients should be prepared to take Wegovy for years since there isn’t an antibiotic for weight”.
People are living longer despite the downturn because of COVID but has anyone asked if they want to live longer? Unless you stay in shape, getting older can be a challenge because of physical and financial problems. We must evaluate whether patients want to live longer with limitations or let nature take its course.
Sales continue to soar for all the weight loss drugs in 2023. Earlier this month, Novo Nordisk told the CBS news program 60 Minutes that the company can finally supply all dose levels of Wegovy. Social media and celebrities drive demand for a drug whose side effects are not yet completely known and cost over $1000 a month.
What happened to journalists that actually think? The latest is “fewer than one-third of the most common drugs featured in direct-to-consumer television advertising were rated as having high therapeutic value.” Really? Did they ever think patients have a choice about what’s considered “therapeutic value”?
According to the latest research, more people trust pharma, but what do they charge? I’m sure they trust the drugs given to help them overcome health issues, but what about pharma’s marketing and corporate governance?
According to STAT News, “it’s time to give up on pharmaceutical companies acting in the public interest over their shareholders’ interests and to start focusing on the systems that enable this behavior.” This is wrong and defeatist.
Based on the available data, I’m not clear and skeptical at this moment,” said Yale professor Reshma Ramachandran. “I would have a lot of reservations about prescribing this. “I do think one of the things that have given us a lot of pause…is the risk and the death issue. Nobody wants to be the clinician prescribing a drug that could potentially harm our patients,” she added.” That is just the tip of the problem.
The FDA has approved an Alzheimer’s drug that slowed the rate of cognitive decline in clinical trials without using an advisory committee. The high drug cost — priced at $26,000 per year, Eisai said — combined with strict restrictions on reimbursement by US government-funded health schemes will severely limit the number of patients able to access the medicine, at least for now. What is going on here?